Study of Different Doses of Irinotecan and Cisplatin for First-line Extensive-stage Small-cell Lung Cancer Treatment
NCT02171325
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
54
Enrollment
OTHER
Sponsor class
Conditions
Small Cell Lung Cancer
Interventions
DRUG:
irinotecan
Sponsor
Guangdong Association of Clinical Trials